Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Odonate Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Odonate Therapeutics, Inc. for you to read. Along with our medical data and news we also list Odonate Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odonate Therapeutics, Inc. Companies for you to search.
California Federal Court Rules that Arcturus is Likely to Succeed on Merits of its Claims Against Payne Further Violations by Payne and His Associates Enjoined to Permit all Arcturus Shareholders to Have a Fully Informed Vote at Upcoming Extraordinary Shareholders Meeting SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, to...
BCell Activating Factor BAFF Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across BCell Activating Factor BAFF Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with comple...
Crescita Therapeutics' new U.S. launch through its partner, Taro Pharmaceuticals of Pliaglis is just one of the many global expansions the company is expecting in the coming years. The post Crescita’s US Prescription Product is “Launching Shortly,” says CEO appeared first on Investing News Network.
According to the World Health Organization, over 216 million people were infected with malaria in 2016, and 445,000 individuals died from the disease. The key to solving this health crisis is early-stage diagnosis when malaria therapeutics are most effective. A new prototype for a portable instrument capable early-stage malaria detection has been developed by a team of researchers at the USC Viter...
Arginine Depletors Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Arginine Depletors development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental st...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer; Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer; John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Devel...
Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.
rEVO Biologics Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your business ...
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously re...
Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of the Company’s ThermoGenesis device division, was recently interviewed by Cell & Gene Therapy Insights. The article, “Driving CAR-T Manufacture Optimization through Technology Innovation,” appear...
BioSensics LLC, has announced the launch of its Sensor-Integrated Digital Platform for measurement and remote monitoring of movement-based biomarkers in
Bryan Irving is now executive vice president and chief scientific officer of Five Prime Therapeutics (NASDAQ: FPRX). Irving first joined South San Francisco-based Five Prime last year as vice president of research. His experience also includes posts at CytomX Therapeutics (NASDAQ: CTMX) and Genentech. Clinical-stage Five Prime develops protein therapies to treat cancer and inflammatory […]
Technavio research analysts have predicted the global chemothera
Several former Insys Therapeutics defendants derided "inflammatory" charges filed against them by the federal government in a filing that seeks to dismiss the case.
Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for ... The post Another Pneumonia Antibiotic is Close to Treating Patients appeared first on Labiotech.eu.
Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that the company would be participating in
H.Lundbeck, a global pharmaceutical company specialized in psychiatric and neurological disorders, has announced that the company further focuses its preclinical research pipeline with the divestment of two research programmes
Wenn du die Nachrichten in letzter Zeit verfolgt hast, hast du vielleicht von der Genbearbeitung gehört, einem Prozess, bei dem die DNA einer Person neu geschrieben wird, um genetische Störungen zu...
Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced that it has received 510(k) clearance from the U. S. Food and Drug Administration (FDA) to market its Catasyn™ Advanced Technology Wound Hydrogel both under the direction of a ...
Translate Bio, a leading messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of John R. Schroer, CFA, as Chief Financial Officer. With 28 years of healthcare investment experience, Mr. Schroer brings expertise in fin...
The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva. Beyond the immediate $70 million investment, the deal is also back loaded with a potential $470 million in regulatory and commercial milestones. read more